Scientists discover how ‘obesity gene’ makes people fat

2013-07-16 08:55

London – Scientists have unravelled how a gene long associated with obesity makes people fat by triggering increased hunger, opening up potential new ways to fight a growing global health problem.

A common variation in the FTO gene affects one in six of the population, making them 70% more likely to become obese – but until now experts did not know why.

Using a series of tests, a British-led research team said they had found people with the variation not only had higher levels of the “hunger hormone” ghrelin in their blood, but also increased sensitivity to the chemical in their brains.

“It’s a double hit,” said Rachel Batterham from University College London, who led the study, which was published in the Journal of Clinical Investigation yesterday.

The discovery follows studies of blood samples from people after meals, combined with functional magnetic resonance imaging of volunteers’ brains and cell-based studies looking at ghrelin production at a molecular level.

Batterham said the work provided new insights and possible new leads for treatment, since some experimental drugs are known to suppress ghrelin and could be particularly effective if targeted at patients with the obesity-risk variant of the gene.

Previous research has also shown ghrelin can be reduced by eating a high-protein diet.

Steve Bloom of Imperial College London, who was not involved in the study, said the FTO gene only explained a small part of the obesity epidemic but the latest discovery was “an important step forward” in unravelling the various factors involved.

The prevalence of obesity is increasing worldwide at an alarming rate and both developed and developing countries are affected. Obesity is a major risk factor for diabetes, heart disease and certain cancers.

At least 2.8 million adults die each year as a result of being overweight or obese, and more than 40 million children under the age of five were overweight in 2011, according to the World Health Organisation.

Developing effective obesity drugs has been a challenge for drugmakers, although some new medicines are now coming through.

After a gap of more than a decade, two new obesity drugs – Vivus Inc’s Qsymia and Arena Pharmaceuticals Inc’s Belviq – were approved by the US Food and Drug Administration last year.

Belviq’s launch was delayed, however, pending a final classification on its risk of abuse and Qsymia’s sales have been disappointing.

- Reuters

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions. publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24


Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.